Drug Trial Radar · NCT07628062
Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation
Last checked: Nov 20, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Jul 22, 2026
Primary completion
Dec 31, 2030
Study completion Jun 27, 2031
Sponsor
- Lead sponsor
- ImmunityBio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2a/2 study evaluates the safety, tolerability, and efficacy of neoadjuvant and adjuvant NAI, hAd5-HPV vaccine (IBRX-042), and nab-paclitaxel in participants with locally advanced HPV-positive oropharyngeal squamous cell carcinoma (OPSCC). The study includes a Phase 2a safety lead-in followed by a randomized Phase 2 comparison of a de-intensified experimental chemoradiation approach versus standard-of-care chemoradiation.
Conditions
- HPV-Positive Oropharyngeal Squamous Cell Carcinoma
- Oropharyngeal Squamous Cell Carcinoma
- Head and Neck Cancer
Interventions
Nogapendekin Alfa Inbakicept (NAI)Drug
NAI 1.2 mg administered subcutaneously as part of the experimental treatment regimen.
hAd5-HPV Vaccine (IBRX-042)Biological
IBRX-042 administered subcutaneously as part of the experimental treatment regimen.
Nab-PaclitaxelDrug
Nab-paclitaxel 100 mg/m² administered intravenously during neoadjuvant treatment cycles.
CisplatinDrug
Cisplatin 40 mg/m² administered intravenously concurrently with radiation therapy.
De-Intensified IMRTRadiation
IMRT 40 Gy, delivered once daily, 5 days/week, over 4 weeks (20 total fractions)
Standard of Care IMRTRadiation
SOC IMRT 70 Gy, delivered once daily, 5 days/week, over 7 weeks (35 total fractions)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS)Time frame: Up to approximately 2 years after completion of treatment
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.